Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Ventricular Tachycardia
Questions discussed in this category
What is your preferred pharmacologic agent for recurrent VT suppression in arrhythmogenic right ventricular cardiomyopathy?
1 Answer available
13777
Papers discussed in this category
Heart rhythm, 2019-11
2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy.
Heart Rhythm, 2015 Sep 30
Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.
J Am Coll Cardiol, 2009 Aug 25
The year in review of clinical cardiac electrophysiology.
Circulation, 1992 Jul
Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia.
Related Topics
Cardiology
Cardiac Electrophysiology